These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36598155)

  • 21. Imaging of HER3-expressing xenografts in mice using a (99m)Tc(CO) 3-HEHEHE-Z HER3:08699 affibody molecule.
    Orlova A; Malm M; Rosestedt M; Varasteh Z; Andersson K; Selvaraju RK; Altai M; Honarvar H; Strand J; Ståhl S; Tolmachev V; Löfblom J
    Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1450-9. PubMed ID: 24622956
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kit formulation for 99mTc-labeling of recombinant anti-HER2 Affibody molecules with a C-terminally engineered cysteine.
    Ahlgren S; Andersson K; Tolmachev V
    Nucl Med Biol; 2010 Jul; 37(5):539-46. PubMed ID: 20610158
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical evaluation of
    Yang Y; Zhao X; Xing Y; Yu T; Zhang J; Wang J
    Oncol Lett; 2018 Oct; 16(4):5361-5366. PubMed ID: 30250607
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules.
    Perols A; Honarvar H; Strand J; Selvaraju R; Orlova A; Karlström AE; Tolmachev V
    Bioconjug Chem; 2012 Aug; 23(8):1661-70. PubMed ID: 22768790
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of 99mTc-Z IGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression.
    Mitran B; Altai M; Hofström C; Honarvar H; Sandström M; Orlova A; Tolmachev V; Gräslund T
    Amino Acids; 2015 Feb; 47(2):303-15. PubMed ID: 25425114
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [99mTc(CO)3]+-(HE)3-ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours.
    Orlova A; Hofström C; Strand J; Varasteh Z; Sandstrom M; Andersson K; Tolmachev V; Gräslund T
    Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):439-49. PubMed ID: 23179942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel small
    Liang Z; Hu X; Hu H; Wang P; Cai J
    Front Oncol; 2022; 12():1017737. PubMed ID: 36387113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule.
    Engfeldt T; Tran T; Orlova A; Widström C; Feldwisch J; Abrahmsen L; Wennborg A; Karlström AE; Tolmachev V
    Eur J Nucl Med Mol Imaging; 2007 Nov; 34(11):1843-53. PubMed ID: 17565496
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Imaging of HER2-Positive Tumors in NOD/SCID Mice with Pertuzumab Fab-Hexahistidine Peptide Immunoconjugates Labeled with [
    Facca VJ; Al-Saden N; Ku A; Reilly RM
    Mol Imaging Biol; 2021 Aug; 23(4):495-504. PubMed ID: 33479914
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HER2-positive tumors imaged within 1 hour using a site-specifically 11C-labeled Sel-tagged affibody molecule.
    Wållberg H; Grafström J; Cheng Q; Lu L; Martinsson Ahlzén HS; Samén E; Thorell JO; Johansson K; Dunås F; Olofsson MH; Stone-Elander S; Arnér ES; Ståhl S
    J Nucl Med; 2012 Sep; 53(9):1446-53. PubMed ID: 22872744
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiolabeled affibody-albumin bioconjugates for HER2-positive cancer targeting.
    Hoppmann S; Miao Z; Liu S; Liu H; Ren G; Bao A; Cheng Z
    Bioconjug Chem; 2011 Mar; 22(3):413-21. PubMed ID: 21299201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake.
    Ekblad T; Tran T; Orlova A; Widström C; Feldwisch J; Abrahmsén L; Wennborg A; Karlström AE; Tolmachev V
    Eur J Nucl Med Mol Imaging; 2008 Dec; 35(12):2245-55. PubMed ID: 18594815
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular Imaging of HER2 Expression in Breast Cancer patients Using the [
    Biabani Ardakani J; Abedi SM; Mardanshahi A; Shojaee L; Zaboli E; Khorramimoghaddam A; Nosrati A; Sabahno H; Banimostafavi ES; Hosseinimehr SJ
    Clin Breast Cancer; 2023 Feb; 23(2):219-230. PubMed ID: 36581518
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors: preclinical assessment.
    Altai M; Wållberg H; Honarvar H; Strand J; Orlova A; Varasteh Z; Sandström M; Löfblom J; Larsson E; Strand SE; Lubberink M; Ståhl S; Tolmachev V
    J Nucl Med; 2014 Nov; 55(11):1842-8. PubMed ID: 25278516
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HEHEHE-tagged affibody molecule may be purified by IMAC, is conveniently labeled with [⁹⁹(m)Tc(CO)₃](+), and shows improved biodistribution with reduced hepatic radioactivity accumulation.
    Tolmachev V; Hofström C; Malmberg J; Ahlgren S; Hosseinimehr SJ; Sandström M; Abrahmsén L; Orlova A; Gräslund T
    Bioconjug Chem; 2010 Nov; 21(11):2013-22. PubMed ID: 20964447
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SPECT/CT Imaging of the Novel HER2-Targeted Peptide Probe
    Li L; Wu Y; Wang Z; Jia B; Hu Z; Dong C; Wang F
    J Nucl Med; 2017 May; 58(5):821-826. PubMed ID: 28104744
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.